Omeros Property, Plant, and Equipment 2010-2024 | OMER
Omeros property, plant, and equipment from 2010 to 2024. Property, plant, and equipment can be defined as the sum of all net property, plant & Equipment fields. Where companies do not report a break down of plant, property, & equipment, the value is entered in this field alone.
| Omeros Annual Property, Plant, and Equipment (Millions of US $) |
|
|---|---|
| 2024 | $3 |
| 2023 | $2 |
| 2022 | $1 |
| 2021 | $2 |
| 2020 | $3 |
| 2019 | $4 |
| 2018 | $4 |
| 2017 | $2 |
| 2016 | $1 |
| 2015 | $1 |
| 2014 | $1 |
| 2013 | $1 |
| 2012 | $1 |
| 2011 | $1 |
| 2010 | $2 |
| 2009 | $1 |
| Omeros Quarterly Property, Plant, and Equipment (Millions of US $) |
|
|---|---|
| 2024-12-31 | $3 |
| 2024-09-30 | $2 |
| 2024-06-30 | $2 |
| 2024-03-31 | $2 |
| 2023-12-31 | $2 |
| 2023-09-30 | $2 |
| 2023-06-30 | $2 |
| 2023-03-31 | $1 |
| 2022-12-31 | $1 |
| 2022-09-30 | $2 |
| 2022-06-30 | $2 |
| 2022-03-31 | $1 |
| 2021-12-31 | $2 |
| 2021-09-30 | $2 |
| 2021-06-30 | $2 |
| 2021-03-31 | $2 |
| 2020-12-31 | $3 |
| 2020-09-30 | $3 |
| 2020-06-30 | $3 |
| 2020-03-31 | $3 |
| 2019-12-31 | $4 |
| 2019-09-30 | $4 |
| 2019-06-30 | $4 |
| 2019-03-31 | $4 |
| 2018-12-31 | $4 |
| 2018-09-30 | $3 |
| 2018-06-30 | $2 |
| 2018-03-31 | $2 |
| 2017-12-31 | $2 |
| 2017-09-30 | $2 |
| 2017-06-30 | $1 |
| 2017-03-31 | $1 |
| 2016-12-31 | $1 |
| 2016-09-30 | $1 |
| 2016-06-30 | $1 |
| 2016-03-31 | $1 |
| 2015-12-31 | $1 |
| 2015-09-30 | $1 |
| 2015-06-30 | $1 |
| 2015-03-31 | $1 |
| 2014-12-31 | $1 |
| 2014-09-30 | $1 |
| 2014-06-30 | $1 |
| 2014-03-31 | $1 |
| 2013-12-31 | $1 |
| 2013-09-30 | $1 |
| 2013-06-30 | $1 |
| 2013-03-31 | $1 |
| 2012-12-31 | $1 |
| 2012-09-30 | $1 |
| 2012-06-30 | $1 |
| 2012-03-31 | $1 |
| 2011-12-31 | $1 |
| 2011-09-30 | $1 |
| 2011-06-30 | $1 |
| 2011-03-31 | $2 |
| 2010-12-31 | $2 |
| 2010-09-30 | $2 |
| 2010-06-30 | $1 |
| 2010-03-31 | $1 |
| 2009-12-31 | $1 |
| 2009-09-30 | $1 |
| 2009-06-30 | |
| 2009-03-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.418B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||